UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

Phase II trials in journal of clinical oncology

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3073-3076

Cannistra, Stephen A

2009

Link zum Volltext

Verfügbarkeit prüfen

Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3555-3561

2010

Link zum Volltext

Verfügbarkeit prüfen

Granulosa Cell Tumor of the Ovary

Journal of clinical oncology, 2003-03, Vol.21 (6), p.1180-1189

2003

Link zum Volltext

Verfügbarkeit prüfen

Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer

Cancer research (Chicago, Ill.), 2011-08, Vol.71 (15), p.5081-5089

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

Journal of clinical oncology, 2007-11, Vol.25 (33), p.5180-5186

2007

Link zum Volltext

Verfügbarkeit prüfen

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Journal of clinical oncology, 2009-11, Vol.27 (33), p.5601-5606

2009

Link zum Volltext

Verfügbarkeit prüfen

Cancer of the Ovary

The New England journal of medicine, 2004-12, Vol.351 (24), p.2519-2529

Cannistra, Stephen A

2004

Link zum Volltext

Verfügbarkeit prüfen

The End of a Fantastic Voyage

Journal of clinical oncology, 2021-05, Vol.39 (15), p.1603-1608

Cannistra, Stephen A

2021

Link zum Volltext

Verfügbarkeit prüfen

Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer

Journal of clinical oncology, 2004-12, Vol.22 (23), p.4700-4658

2004

Link zum Volltext

Verfügbarkeit prüfen

Journal of Clinical Oncology’s Data Sharing Policy for Clinical Trials

Journal of clinical oncology, 2019-12, Vol.37 (35), p.3333-3334

Cannistra, Stephen A.

2019

Link zum Volltext

Verfügbarkeit prüfen

Challenges Faced by Medical Journals During the COVID-19 Pandemic

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2206-2207

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Müllerian Tumors

Journal of clinical oncology, 2010-01, Vol.28 (1), p.154-159

2010

Link zum Volltext

Verfügbarkeit prüfen

Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7911-7918

2005

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

Journal of clinical oncology, 2021-06, Vol.39 (17), p.JCO2100571-1838

2021

Link zum Volltext

Verfügbarkeit prüfen

Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer

Journal of clinical oncology, 2019-09, Vol.37 (27), p.2424-2436

2019

Link zum Volltext

Verfügbarkeit prüfen

Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?

Journal of clinical oncology, 2019-06, Vol.37 (16), p.1359-1364

2019

Link zum Volltext

Verfügbarkeit prüfen

Progress and Promise in Treating Gynecologic Cancers

Journal of clinical oncology, 2019-09, Vol.37 (27), p.2383-2385

2019

Link zum Volltext

Verfügbarkeit prüfen

Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer

PloS one, 2011-03, Vol.6 (3), p.e18202-e18202

2011

Link zum Volltext

Verfügbarkeit prüfen

Reply to R.J. Buckanovich et al

Journal of clinical oncology, 2019-10, Vol.37 (29), p.2708-2709

2019

Link zum Volltext

Verfügbarkeit prüfen

In the Pursuit of Excellence: Reflections From the Editor-in-Chief of Journal of Clinical Oncology

Journal of clinical oncology, 2016-10, Vol.34 (30), p.3589-3590

Cannistra, Stephen A

2016

Link zum Volltext

Verfügbarkeit prüfen

Maintenance PARP inhibitor therapy: is maintaining quality of life enough?

The lancet oncology, 2018-10, Vol.19 (10), p.e504-e504

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2786-2794

2019

Link zum Volltext

Verfügbarkeit prüfen

BAX Enhances Paclitaxel-Induced Apoptosis through a p53-Independent Pathway

Proceedings of the National Academy of Sciences - PNAS, 1996-11, Vol.93 (24), p.14094-14099

1996

Link zum Volltext

Verfügbarkeit prüfen

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

Journal of clinical oncology, 2010-07, Vol.28 (19), p.3101-3103

Cannistra, Stephen A

2010

Link zum Volltext

Verfügbarkeit prüfen

Challenges and pitfalls of combining targeted agents in phase I studies

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3665-3667

Cannistra, Stephen A

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(117)
Buchkapitel
(1)

Sprache

Englisch
(118)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Humans
(84)
Life Sciences & Biomedicine
(82)
Oncology
(58)
Female
(57)
Biological And Medical Sciences
(46)
Medical Sciences
(34)
Tumors
(25)
Ovarian Neoplasms - Drug Therapy
(22)
Female Genital Diseases
(21)
Gynecology. Andrology. Obstetrics
(21)
Middle Aged
(21)
Ovarian Neoplasms - Pathology
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Ovarian Cancer
(17)
Adult
(16)
Aged
(15)
Ovarian Neoplasms - Genetics
(14)
Treatment Outcome
(13)
Fundamental And Applied Biological Sciences. Psychology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II trials in journal of clinical oncology

Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

Granulosa Cell Tumor of the Ovary

Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer

Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Cancer of the Ovary

The End of a Fantastic Voyage

Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer

Journal of Clinical Oncology’s Data Sharing Policy for Clinical Trials

Challenges Faced by Medical Journals During the COVID-19 Pandemic

Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Müllerian Tumors

Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer

Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer

Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?

Progress and Promise in Treating Gynecologic Cancers

Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer

Reply to R.J. Buckanovich et al

In the Pursuit of Excellence: Reflections From the Editor-in-Chief of Journal of Clinical Oncology

Maintenance PARP inhibitor therapy: is maintaining quality of life enough?

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

BAX Enhances Paclitaxel-Induced Apoptosis through a p53-Independent Pathway

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

Challenges and pitfalls of combining targeted agents in phase I studies

Suchergebnisse filtern